Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Yelensky

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Genetic Epidemiology|March 19, 2008
Estimation of the multiple testing burden for genomewide association studies of nearly all common variantsItsik Pe'er, Roman Yelensky, David Altshuler, et al.
Trends in Immunology|May 13, 2018
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be DifferentChung-Han Lee, Roman Yelensky, Karin Jooss, et al.
Nature Genetics|May 23, 2006
Evaluating and improving power in whole-genome association studies using fixed marker setsItsik Pe'er, Paul I W de Bakker, Julian Maller, et al.
Nature Genetics|October 26, 2005
Efficiency and power in genetic association studiesPaul I W de Bakker, Roman Yelensky, Itsik Pe'er, et al.
BMC Cancer|May 30, 2015
Multiple gene aberrations and breast cancer: lessons from super-respondersJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
BMC Cancer|April 18, 2015
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistanceJennifer Wheler, Roman Yelensky, Gerald Falchook, et al.
Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Journal of the National Cancer Institute|November 14, 2015
Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to CrizotinibVictor Wong, Dean Pavlick, Tim Brennan, et al.
Oncotarget|June 15, 2013
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analysesJennifer Wheler, David Hong, Stephen G Swisher, et al.
Journal of Clinical Pathology|October 27, 2015
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targetsHwajeong Lee, Kai Wang, Adrienne Johnson, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Genetic Epidemiology|March 19, 2008
Estimation of the multiple testing burden for genomewide association studies of nearly all common variantsItsik Pe'er, Roman Yelensky, David Altshuler, et al.
Trends in Immunology|May 13, 2018
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be DifferentChung-Han Lee, Roman Yelensky, Karin Jooss, et al.
Nature Genetics|May 23, 2006
Evaluating and improving power in whole-genome association studies using fixed marker setsItsik Pe'er, Paul I W de Bakker, Julian Maller, et al.
Nature Genetics|October 26, 2005
Efficiency and power in genetic association studiesPaul I W de Bakker, Roman Yelensky, Itsik Pe'er, et al.
BMC Cancer|May 30, 2015
Multiple gene aberrations and breast cancer: lessons from super-respondersJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
BMC Cancer|April 18, 2015
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistanceJennifer Wheler, Roman Yelensky, Gerald Falchook, et al.
Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Journal of the National Cancer Institute|November 14, 2015
Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to CrizotinibVictor Wong, Dean Pavlick, Tim Brennan, et al.
Oncotarget|June 15, 2013
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analysesJennifer Wheler, David Hong, Stephen G Swisher, et al.
Journal of Clinical Pathology|October 27, 2015
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targetsHwajeong Lee, Kai Wang, Adrienne Johnson, et al.
Pageof 8